A Randomised, Single Blind, Cross-over Study to Compare a Fixed Dose Combination of Fluticasone Propionate / Formoterol Fumarate (Breath Actuated Inhaler (BAI)) With a Fixed Dose Combination of Indacaterol Maleate / Glycopyrronium Bromide (Ultibro® Breezhaler) in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

Trial Profile

A Randomised, Single Blind, Cross-over Study to Compare a Fixed Dose Combination of Fluticasone Propionate / Formoterol Fumarate (Breath Actuated Inhaler (BAI)) With a Fixed Dose Combination of Indacaterol Maleate / Glycopyrronium Bromide (Ultibro® Breezhaler) in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary) ; Glycopyrrolate/indacaterol
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Mundipharma Research
  • Most Recent Events

    • 09 Dec 2016 Status changed from recruiting to discontinued.
    • 09 Dec 2016 The trial has been completed in Hungary (end date: 2016-11-07).
    • 09 Dec 2016 The trial has been Discontinued in Poland.(end date: 2016-11-07).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top